James R. Gavin III, MD, PhD

James Gavin III, MD, PhD
 

Clinical Professor of Medicine
Emory University School of Medicine
Atlanta, Georgia
Clinical Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana

Why, in both ADA and AACE guidelines statements, do GLP-1 receptor agonists represent a foundational approach for management of T2D? Video

Why, in both ADA and AACE guidelines statements, do GLP-1 receptor agonists represent a foundational approach for management of T2D?

Why, in both ADA and AACE guidelines statements, do GLP-1 receptor agonists represent a foundational approach for management of T2D?
James Gavin III, MD, PhD

James Gavin III, MD, PhD

In what setting and in what patient profiles do GLP-1 RAs make most sense? What degrees of HA1c reduction are seen? Video

In what setting and in what patient profiles do GLP-1 RAs make most sense? What degrees of HA1c reduction are seen?

In what setting and in what patient profiles do GLP-1 RAs make most sense? What degrees of HA1c reduction are seen?
James Gavin III, MD, PhD

James Gavin III, MD, PhD

What is the rationale, therefore, of combining GLP-1 RAs and basal insulin into fixed ratio combination agents? Video

What is the rationale, therefore, of combining GLP-1 RAs and basal insulin into fixed ratio combination agents?

What is the rationale, therefore, of combining GLP-1 RAs and basal insulin into fixed ratio combination agents?
James Gavin III, MD, PhD

James Gavin III, MD, PhD

Can you provide clinical profiles where there is a strong rationale to move from a regimen of metformin and SGLT2 inhibitor, to a fixed ratio combination of a basal insulin plus GLP-1 RA? Video

Can you provide clinical profiles where there is a strong rationale to move from a regimen of metformin and SGLT2 inhibitor, to a fixed ratio combination of a basal insulin plus GLP-1 RA?

Can you provide clinical profiles where there is a strong rationale to move from a regimen consisting of metformin and SGLT2 inhibitor, to a fixed ratio combination of a basal insulin plus GLP-1 RA?
James Gavin III, MD, PhD

James Gavin III, MD, PhD

What is the importance of postprandial hyperglycemia (PPG) and glucose excursions as a management metric and what are the implications for selecting GLP-1 RAs? Video

What is the importance of postprandial hyperglycemia (PPG) and glucose excursions as a management metric and what are the implications for selecting GLP-1 RAs?

What is the importance of postprandial hyperglycemia (PPG) and glucose excursions as a management metric and what are the implications for selecting GLP-1 RAs?
James Gavin III, MD, PhD

James Gavin III, MD, PhD